Free Trial

BioRestorative Therapies Q1 2024 Earnings Report

BioRestorative Therapies logo
$1.55 +0.10 (+6.90%)
(As of 12/20/2024 05:51 PM ET)

BioRestorative Therapies EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

BioRestorative Therapies Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.03 million
Beat/Miss
Beat by +$10.00 thousand
YoY Revenue Growth
N/A

BioRestorative Therapies Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

BioRestorative Therapies Earnings Headlines

Roth MKM Remains a Buy on BioRestorative Therapies (BRTX)
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More BioRestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioRestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioRestorative Therapies and other key companies, straight to your email.

About BioRestorative Therapies

BioRestorative Therapies (OTCMKTS:BRTX) engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

View BioRestorative Therapies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings